Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking

Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking

Thumbnail Image
Download
Name

s41598-022-18580-3.pdf

Description
Published version
Size

6.35 MB

Format

Adobe PDF

Checksum (MD5)

640a8b00983e3e004b1f06ee124d4a7a

sword-2023-02-06T19:52:20.original.xml (130 B)
Original SWORD entry document
Author(s)
Kanhasut, Karnpob
•
Tharakaraman, Kannan
•
Ruchirawat, Mathuros
•
Satayavivad, Jutamaad
•
Fuangthong, Mayuree
•
Sasisekharan, Ram
Date Issued
2022
Journal
Scientific Reports
Publisher
Springer Science and Business Media LLC
Citation
Kanhasut, Karnpob, Tharakaraman, Kannan, Ruchirawat, Mathuros, Satayavivad, Jutamaad, Fuangthong, Mayuree et al. 2022. "Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking." Scientific Reports, 12 (1).
Version
Final published version
Abstract
AbstractBurosumab, an FGF23 targeting monoclonal antibody, was approved by the FDA in 2018 for use in children and adults with X-linked hypophosphatemia (or XLH). While several clinical studies have demonstrated the long-term safety and efficacy of Burosumab, the molecular basis of FGF23-Burosumab interaction which underpins its mechanism of action remains unknown. In this study, we employed molecular docking combined with alanine scanning of epitope and paratope to predict a model of FGF23-Burosumab interaction. Then, we used the model to understand the species-species cross-reactivity of Burosumab and to reverse engineer mouse FGF23 with 'back to human' mutations to bind Burosumab. Finally, we redesigned the CDRs with two mutations to engineer an affinity enhanced variant of the antibody. Our study provides insights into the FGF23-Burosumab interaction and demonstrates that alanine-scanning coupled with molecular docking can be used to optimize antibody candidates (e.g., structure-guided affinity maturation) for therapeutic use.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution 4.0 International license
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/147919
DOI of Published Version
https://doi.org/10.1038/S41598-022-18580-3
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.